Analysis of SMAD4 gene promoter methylation in pancreatic and endometrial cancers
Authors
Nikolić, AleksandraOpinćal, Filip
Ristanović, Momčilo
Trifunović, Jovanka
Knežević, Srbislav
Radojković, Dragica
Article (Published version)
Metadata
Show full item recordAbstract
Promoter hypermethylation of the SMAD4 gene has been registered in some cancer types, but in general doesn't appear to be a frequent event in carcinogenesis. However, only a few published studies deal with this topic and not many cancer types have been analyzed. The aim of this study was to establish SMAD4 gene promoter methylation status in pancreatic and endometrial cancers. Methods. Patients included in the study (62 subjects) were diagnosed and surgically treated at the University of Belgrade, Clinical Center of Serbia. Patients with pancreatic carcinoma (17 subjects) underwent surgical removal of the pancreatic adenocarcinoma at the First Surgical Clinic, while the patients with endometrial carcinoma (45 subjects) underwent hysterectomy with adnexectomy at the Institute for Gynecology and Obstetrics. Extraction of DNA from fresh tissue samples was performed and the methylation status of the SMAD4 gene promoter was studied by a previously designed PCR-based HpaII and MspI restricti...on enzyme assay. The resulting PCR products were analyzed by electrophoresis in 2% agarose gels. Results. Neither of the analyzed samples was found to be hypermethylated. Conclusion. This is the first report on SMAD4 methylation status in pancreatic and endometrial tumor specimens, and supports the viewpoint that SMAD4 hypermethylation is not a common event in malignant tumors. Nevertheless, promoter hypermethylation remains a candidate mechanism for SMAD4 inactivation in malignant tissue as a potential cause of decreased or lost SMAD4 expression in certain tumor types, and should be further investigated in different tumor types and larger cohorts of patients.
Keywords:
pancreatic cancer / Methylation / endometrial cancerSource:
Archive of Oncology, 2017, 23, 2, 17-19Publisher:
- Institut za onkologiju, Sremska Kamenica
Funding / projects:
- Complex diseases as a model system for phenotype modulation- structural and functional analysis of molecular biomarkers (RS-MESTD-Basic Research (BR or ON)-173008)
Collections
Institution/Community
Institut za molekularnu genetiku i genetičko inženjerstvoTY - JOUR AU - Nikolić, Aleksandra AU - Opinćal, Filip AU - Ristanović, Momčilo AU - Trifunović, Jovanka AU - Knežević, Srbislav AU - Radojković, Dragica PY - 2017 UR - https://imagine.imgge.bg.ac.rs/handle/123456789/1028 AB - Promoter hypermethylation of the SMAD4 gene has been registered in some cancer types, but in general doesn't appear to be a frequent event in carcinogenesis. However, only a few published studies deal with this topic and not many cancer types have been analyzed. The aim of this study was to establish SMAD4 gene promoter methylation status in pancreatic and endometrial cancers. Methods. Patients included in the study (62 subjects) were diagnosed and surgically treated at the University of Belgrade, Clinical Center of Serbia. Patients with pancreatic carcinoma (17 subjects) underwent surgical removal of the pancreatic adenocarcinoma at the First Surgical Clinic, while the patients with endometrial carcinoma (45 subjects) underwent hysterectomy with adnexectomy at the Institute for Gynecology and Obstetrics. Extraction of DNA from fresh tissue samples was performed and the methylation status of the SMAD4 gene promoter was studied by a previously designed PCR-based HpaII and MspI restriction enzyme assay. The resulting PCR products were analyzed by electrophoresis in 2% agarose gels. Results. Neither of the analyzed samples was found to be hypermethylated. Conclusion. This is the first report on SMAD4 methylation status in pancreatic and endometrial tumor specimens, and supports the viewpoint that SMAD4 hypermethylation is not a common event in malignant tumors. Nevertheless, promoter hypermethylation remains a candidate mechanism for SMAD4 inactivation in malignant tissue as a potential cause of decreased or lost SMAD4 expression in certain tumor types, and should be further investigated in different tumor types and larger cohorts of patients. PB - Institut za onkologiju, Sremska Kamenica T2 - Archive of Oncology T1 - Analysis of SMAD4 gene promoter methylation in pancreatic and endometrial cancers EP - 19 IS - 2 SP - 17 VL - 23 DO - 10.2298/AOO1702017N ER -
@article{ author = "Nikolić, Aleksandra and Opinćal, Filip and Ristanović, Momčilo and Trifunović, Jovanka and Knežević, Srbislav and Radojković, Dragica", year = "2017", abstract = "Promoter hypermethylation of the SMAD4 gene has been registered in some cancer types, but in general doesn't appear to be a frequent event in carcinogenesis. However, only a few published studies deal with this topic and not many cancer types have been analyzed. The aim of this study was to establish SMAD4 gene promoter methylation status in pancreatic and endometrial cancers. Methods. Patients included in the study (62 subjects) were diagnosed and surgically treated at the University of Belgrade, Clinical Center of Serbia. Patients with pancreatic carcinoma (17 subjects) underwent surgical removal of the pancreatic adenocarcinoma at the First Surgical Clinic, while the patients with endometrial carcinoma (45 subjects) underwent hysterectomy with adnexectomy at the Institute for Gynecology and Obstetrics. Extraction of DNA from fresh tissue samples was performed and the methylation status of the SMAD4 gene promoter was studied by a previously designed PCR-based HpaII and MspI restriction enzyme assay. The resulting PCR products were analyzed by electrophoresis in 2% agarose gels. Results. Neither of the analyzed samples was found to be hypermethylated. Conclusion. This is the first report on SMAD4 methylation status in pancreatic and endometrial tumor specimens, and supports the viewpoint that SMAD4 hypermethylation is not a common event in malignant tumors. Nevertheless, promoter hypermethylation remains a candidate mechanism for SMAD4 inactivation in malignant tissue as a potential cause of decreased or lost SMAD4 expression in certain tumor types, and should be further investigated in different tumor types and larger cohorts of patients.", publisher = "Institut za onkologiju, Sremska Kamenica", journal = "Archive of Oncology", title = "Analysis of SMAD4 gene promoter methylation in pancreatic and endometrial cancers", pages = "19-17", number = "2", volume = "23", doi = "10.2298/AOO1702017N" }
Nikolić, A., Opinćal, F., Ristanović, M., Trifunović, J., Knežević, S.,& Radojković, D.. (2017). Analysis of SMAD4 gene promoter methylation in pancreatic and endometrial cancers. in Archive of Oncology Institut za onkologiju, Sremska Kamenica., 23(2), 17-19. https://doi.org/10.2298/AOO1702017N
Nikolić A, Opinćal F, Ristanović M, Trifunović J, Knežević S, Radojković D. Analysis of SMAD4 gene promoter methylation in pancreatic and endometrial cancers. in Archive of Oncology. 2017;23(2):17-19. doi:10.2298/AOO1702017N .
Nikolić, Aleksandra, Opinćal, Filip, Ristanović, Momčilo, Trifunović, Jovanka, Knežević, Srbislav, Radojković, Dragica, "Analysis of SMAD4 gene promoter methylation in pancreatic and endometrial cancers" in Archive of Oncology, 23, no. 2 (2017):17-19, https://doi.org/10.2298/AOO1702017N . .